Evolus celebrates greenlight for Botox rival while Allergan counterattacks with a complaint of stolen trade secrets
Despite a months-long delay, Evolus has overcome manufacturing faults FDA previously found and managed to secure a nod to begin marketing its Botox rival. And you can count on Allergan to mount a legal counterattack to block the US entry of a biologic that can threaten its $3.5 billion franchise.
The approval came just after market close on Friday for Jeuveau, a 900 kDa purified botulinum toxin type A formulation that reduces frown lines — or “glabellar lines associated with corrugator and/or procerus muscle activity in adults” if you prefer the academic term.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.